Skip to main content
Publications
Kirkeleit J, Riise T, Wielscher M, Accordini S, Carsin AE , Dratva J, Franklin KA, Garcia-Aymerich J, Jarvis D, Leynaert B, Lodge CJ, Real FG, Schlunssen V, Corsico AG, Heinrich J, Holm M, Janson C, Benediktsdottir B, Jogi R, Dharmage SC, Jarvelin MR, Svanes C. Early life exposures contributing to accelerated lung function decline in adulthood - a follow-up study of 11,000 adults from the general population . EClinicalMedicine. 2023 Dec 8;66:102339. doi: 10.1016/j.eclinm.2023.102339
Chamandi C, Barbanti M, Munoz-Garcia A, Latib A, Nombela-Franco L, Gutierrez-Ibanez E, Veiga-Fernandez G, Cheema AN, Cruz-Gonzalez I, Serra V, Tamburino C, Mangieri A, Colombo A, Jimenez-Quevedo P, Elizaga J, Laughlin G, Lee DH, Garcia Del Blanco B, Rodriguez-Gabella T, Marsal JR , Cote M, Philippon F, Rodes-Cabau J. Long-term outcomes in patients with new permanent pacemaker implantation following transcatheter aortic valve replacement . JACC Cardiovasc Interv. 2018 Feb 12;11(3):301-10. doi: 10.1016/j.jcin.2017.10.032
Abdul-Jawad Altisent O, Durand E, Munoz-Garcia AJ, Nombela-Franco L, Cheema A, Kefer J, Gutierrez E, Benitez LM, Amat-Santos IJ, Serra V, Eltchaninoff H, Alnasser SM, Elizaga J, Dager A, Garcia Del Blanco B, Ortas-Nadal MDR, Marsal JR , Campelo-Parada F, Regueiro A, Del Trigo M, Dumont E, Puri R, Rodes-Cabau J. Reply: antithrombotic regimen in post-TAVR atrial fibrillation: not an easy decision . JACC Cardiovasc Interv. 2016 Nov 28;9(22):2366-8. doi: 10.1016/j.jcin.2016.09.038
Abdul-Jawad Altisent O, Durand E, Munoz-Garcia AJ, Nombela-Franco L, Cheema A, Kefer J, Gutierrez E, Benitez LM, Amat-Santos IJ, Serra V, Eltchaninoff H, Alnasser SM, Elizaga J, Dager A, Garcia Del Blanco B, Ortas-Nadal Mdel R, Marsal JR , Campelo-Parada F, Regueiro A, Del Trigo M, Dumont E, Puri R, Rodes-Cabau J. Warfarin and antiplatelet therapy versus Warfarin alone for treating patients with atrial fibrillation undergoing transcatheter aortic valve replacement . JACC Cardiovasc Interv. 2016 Aug 22;9(16):1706-17. doi: 10.1016/j.jcin.2016.06.025
MacDougall JE, Johnston JM, Lavins BJ, Nelson LM , Williams VS , Carson RT, Shiff SJ, Shi K, Kurtz CB, Baird MJ, Currie MG, Lembo AJ. An evaluation of the FDA Responder Endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials . Neurogastroenterol Motil. 2013 Jun;25(6):481-6. doi: 10.1111/nmo.12089